1. Home
  2. TRAX vs EE Comparison

TRAX vs EE Comparison

Compare TRAX & EE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRAX

First Tracks Biotherapeutics Inc. Ordinary Shares

HOLD

Current Price

$43.77

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Excelerate Energy Inc.

EE

Excelerate Energy Inc.

HOLD

Current Price

$32.48

Market Cap

1.2B

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRAX
EE
Founded
2025
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil/Gas Transmission
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2026
2022

Fundamental Metrics

Financial Performance
Metric
TRAX
EE
Price
$43.77
$32.48
Analyst Decision
Strong Buy
Buy
Analyst Count
12
13
Target Price
★ $74.17
$43.46
AVG Volume (30 Days)
★ 1.1M
305.5K
Earning Date
11-12-2026
11-04-2026
Dividend Yield
N/A
★ 1.14%
EPS Growth
N/A
★ 0.79
EPS
N/A
★ 0.75
Revenue
N/A
★ $1,228,263,000.00
Revenue This Year
N/A
$24.05
Revenue Next Year
N/A
$27.03
P/E Ratio
★ N/A
$42.05
Revenue Growth
N/A
★ 44.26
52 Week Low
$15.69
$24.89
52 Week High
$49.91
$43.18

Technical Indicators

Market Signals
Indicator
TRAX
EE
Relative Strength Index (RSI) 65.36 42.09
Support Level $40.72 $31.74
Resistance Level $48.94 $35.74
Average True Range (ATR) 3.24 1.13
MACD 1.47 -0.03
Stochastic Oscillator 92.13 26.96

Price Performance

Historical Comparison
TRAX
EE

About TRAX First Tracks Biotherapeutics Inc. Ordinary Shares

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

About EE Excelerate Energy Inc.

Excelerate Energy Inc. offers comprehensive LNG solutions by providing integrated services throughout the LNG value chain. The company delivers a full range of regasification services, including Floating Storage and Regasification Units (FSRUs), infrastructure development, and the supply of LNG and natural gas. With operational presence in several countries - Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States. The company generates revenue through Terminal Services, as well as from LNG, gas, and power. These revenues are derived from its vertically integrated activities in LNG sourcing, transportation, regasification, and power generation.

Share on Social Networks: